DON Healthcare’s Post

Proud to announce that Mermaid Bio GmbH and their CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October. Sophisticated investors, decision makers, and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEO's, Founders, decision makers and sophisticated investors. Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8

Proud to announce that Mermaid Bio GmbH and their CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October. Sophisticated investors, decision makers, and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEO's, Founders, decision makers and sophisticated investors. Mermaid Bio GmbH’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8

Proud to announce that Mermaid Bio GmbH and the CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October 2024. Sophisticated investors, decision makers and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEOs, Founders, decision makers and sophisticated investors. Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8 hashtag #ceos hashtag #investors hashtag #fundraising Activate to view larger image,

Proud to announce that Mermaid Bio GmbH and their CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October. Sophisticated investors, decision makers, and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEO's, Founders, decision makers and sophisticated investors. Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8 #Biotech #BiotechLeaders #LifeSciences #Healthcare #BiotechInvestors #BiotechStartups #MedTech

Congratulations to Babson Diagnostics for being named Medtech Company of the Year by both MD+DI Editors and Readers!! This sampling of survey comments by readers really sums it up: - Great mission, doing things that others couldn't - #Groundbreaking technology and legitimate capillary testing could be a game changer for patients - #Accessibility. I wish this had been in place when I had to continually take my mom to labs for bloodwork. - Making routine blood testing more accessible and #convenient will have a profound impact on the entire #healthcare system. They achieved commercial readiness and launch this year, and clinicians and providers all rave about the experience so far. - Potential massive impact in cost and convenience Truly exciting, game-changing work underway! Editors' Choice announcement: https://lnkd.in/eCSUg9tu Readers' Choice announcement: https://lnkd.in/e-JJCpwn #VC #patientcare #innovation #BackedByEmerald #patientexperience #changetheworld

Thank you Teresa Harris Graham for sharing! Roche's vision for establishing collaborations to improve care has transcended Basel, reaching multiple geographies, thanks to your support to the Movement Health Foundation too. The partnerships with corporations from diverse industries, ministries of health, and local leaders, achieved the following outcomes in 2024: ✅ Peru & South Africa: Our Empowering Women to Live Cancer-Free projects were recognized as a CGI commitment. ✅ Mexico: Published a Health Data Dashboard for 8.9 million beneficiaries in Mexico City, transforming decision-making for the Mexico City Health Secretariat. ✅ Ghana: The Digital Pharmacy Platform secured reimbursement from the Ghana National Health Insurance Scheme for enhanced hypertension care for 87,000 patients, enrolling 70 care centers. ✅ Chile: the National Health Data Governance open consultations to scale up digital health were held. ✅ Bulgaria: Established a tri-partite collaboration agreement with the Helsinki University Hospital (HUS) and the Bulgaria National Health Information System (NHIS), leveraging Finnish expertise for the National Digitalized Patient Journey to ensure reliable, detailed, and verified treatment information for long-term and chronic conditions.

Let me just say this.... My Galderma team came through clutch on the education and insight today. Il-31 is about to change the game. (this is not a claim, just my opinion) #MyTeamIsBetterThanYours #ArgueWithYourMommaNotMe! Let's play trivia: What can happen at 2 days? What's the importance of 90 days? What needs to happen at 4 hours? What was the importance of 540? What took place at week 16? What country is head quarters for Galderma? How does Nemolizumab work?

Lantheus Holdings has signed a #definitiveagreement to acquire Evergreen Theragnostics, in an all-cash transaction consisting of an upfront payment of USD 250 million and up to an additional USD 752.5 million in potential milestone payments. Brian Markison James Cook #healthcare #PharmaIndustrialIndia

Biotest and SteinCares: Partner to improve access to plasma-derived products in Latin America   We are happy to announce, that we have signed a new distribution agreement with SteinCares, a leading specialty healthcare company in Latin America, for the commercialization and distribution of our plasma-derived factor VIII product in Chile, Colombia, Costa Rica, Ecuador, Mexico and Peru.   The product is indicated for the treatment and prophylaxis of bleeding in patients with hemophilia A, offers an accessible alternative compared to other available treatments. As a plasma-derived product, it ensures fast and reliable efficacy, high purity and a favorable safety profile and thus reduces the risk of long-term complications of hemophilia.   Hemophilia therapies are essential for the management of this disease, which affects approximately 56,000 people in Latin America. However, according to the World Federation of Hemophilia, only 57% of these patients are diagnosed and approximately 40% have access to prophylactic treatment. With the introduction in Latin America, we reaffirms our commitment to improving patient access to specialty treatments.   "We are pleased to partner with SteinCares, whose financial and strategic reliability is a key driver for us to begin penetrating the Latin American markets with our products, where economic and political challenges have historically presented opportunities for resilient and innovative growth,” indicates Enrico D'Aiuto, Senior Vice President Commercial Operations at Biotest.   “With this first agreement we are making our Factor VIII product available to hemophilia patients in Latin America. SteinCares' deep-rooted presence and established operations throughout the region, gives us confidence that this agreement will be a success and will be the first step in expanding our commercial footprint in the LATAM region” highlights Carolin Shah, Vice President responsible for the Business Unit Distribution Partners at Biotest.   #Biotest #FromNatureForLife #Healthcare #SteinCares #DistributionAgreement #Hemophilia

We're honored to welcome PetVivo Holdings Inc to participate in the upcoming B2i Digital Featured Conference: Spartan Capital Securities, LLC Investor Conference 2024. The event is scheduled for November 4th at The Pierre Hotel in New York City. About PetVivo Inc: PetVivo Inc. is based in Minneapolis, Minnesota. It is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize medical devices and therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to internally develop and/or in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals. PetVivo Holdings Inc's leadership team includes John Lai, Garry Lowenthal, CMC, Randall Meyer, John Dolan, April B., John Wilhelm, Bryan Monninger and many other talented individuals. Conference attendees will be uniquely able to engage directly with executives, gaining valuable insights into the company’s developments. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities. For those interested in attending this exclusive event, please submit a request to participate at https://lnkd.in/e6ZQhZyA Kindly note that attendance is limited and subject to approval. Thank you to our hosts at Spartan Capital: John D. Lowry, Kim Monchik, Joe Giamichael, Stephen Faucetta, Julia Voss, William Birney, Donald Powell, Louis Valdez, Abdiell (AJ) Suero, Blake Weltmann, Ralph Metz and many others. #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024